<DOC>
<DOCNO>
EP-0002624
</DOCNO>
<TEXT>
<DATE>
19790627
</DATE>
<IPC-CLASSIFICATIONS>
C07C-205/00 C07D-265/00 C07C-205/58 A61K-31/55 A61P-9/00 C07C-29/00 C07C-205/57 C07D-209/38 <main>C07D-223/16</main> C07D-223/16 C07D-209/00 C07D-265/26 C07C-29/147 C07D-223/00 
</IPC-CLASSIFICATIONS>
<TITLE>
2-benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
smithkline corpus<sep>smithkline corporation<sep>smithkline beckman corporationp.o. box 7929 1 franklin plazaphiladelphia pennsylvania 19101us<sep>smithkline beckman corporation<sep>
</APPLICANT>
<INVENTOR>
bondinell william edward<sep>pendleton robert grubb<sep>bondinell, william edward<sep>pendleton, robert grubb<sep>bondinell, william edward46 curtis avenuecherry hill new jersey 08002us<sep>pendleton, robert grubb720 cornelia placephiladelphia pennsylvania 19118us<sep>bondinell, william edward<sep>pendleton, robert grubb<sep>bondinell, william edward46 curtis avenuecherry hill new jersey 08002us<sep>pendleton, robert grubb720 cornelia placephiladelphia pennsylvania 19118us<sep>
</INVENTOR>
<ABSTRACT>
this invention concerns a process for preparing 2-benzazepine  compounds which inhibit the enzyme phenylethanolamine  n-methyltransferase and show activity in  reducing anxiety.  the compounds produced have substituents  in the 8- and/or 9-positions, and optionally substituents  in the 1- and 2-positions.  the compounds are  prepared by debenzylating an appropriately substituted  n-benzyl 2-benzazepine with optional acylation and reduction,  or with optional ozidation and alkylation of the debenzylated  product to introduce 2- and 1-position substituents,  respectively.  acid addition salts of the compounds are also  prepared.  
</ABSTRACT>
</TEXT>
</DOC>
